Document is current

Article History

First Online: 11 August 2020

Declarations

:

: No funding was received specifically for the preparation of this article.

: Dr. Kantrowitz reports having received consulting payments within the last 24 months from Krog & Partners Incorporated, Alphasights, Charles River Associates, Putnam Associates, Third Bridge, Piper Jaffray, MEDACorp, Simon Kucher, LifeSci Capital, ECRI Institute, ExpertConnect, Cellohealth, Acsel Health, Strafluence, Guidepoint, L.E.K. and System Analytic. He has served on the Aristada Schizophrenia Advisory Board for Alkermes and the MedinCell Psychiatry Advisory Board. He has conducted clinical research supported by the NIMH, Roche, Sunovion, the Stanley Foundation, Takeda, Taisho, Lundbeck, Boehringer Ingelheim, NeuroRX, Teva and Lilly within the last 24 months. Dr. Kantrowitz is a co-investigator on a study that receives lumeteperone and reimbursement for safety testing for investigator-initiated research from Intra-Cellular Therapies Inc. He owns a small number of shares of common stock from GSK.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.